Immunoconjugates targeting CD46 and methods of use thereof
US12144888B2 · kind B2 · utility
0Cited by
160References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2022 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | Jun 28, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/3069
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.